Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?

Oncology

Volumn 62, Issue 2, 2002, Pages 115-120

  Liberopoulos, Evagellos ^a   Karabina, Sonia Athena ^a   Tselepis, Alexandros ^a   Bairaktari, Eleni ^a   Nicolaides, Costas ^a   Pavlidis, Nikolaos ^a   Elisaf, Moses ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apolipoprotein E phenotypes; Apolipoproteins; Cholesterol; Lipid parameters; Lipoprotein (a); Tamoxifen

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GENE FREQUENCY; HUMAN; ISOELECTRIC FOCUSING; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; PHENOTYPE; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; APOLIPOPROTEINS E; BREAST NEOPLASMS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; PHENOTYPE; POSTMENOPAUSE; TAMOXIFEN; TRIGLYCERIDES;

EID: 0036207625     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048256     Document Type: Article

References (27)

1. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
2. Apolipoprotein E polymorphism in health and disease
3. Apolipoprotein E polymorphism and atherosclerosis
4. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol
5. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA inhibitor therapy
6. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?
7. Estrogen replacement therapy, serum lipids, and polymorphism of the apolipoprotein E gene
8. Relationship between apolipoprotein E polymorphism, menopausal symptoms, and serum lipids during hormone replacement therapy
9. The beneficial effect of tamoxifen on serum lipoprotein-a levels: An additional anti-atherogenic property
10. Tamoxifen, serum lipoproteins and cardiovascular risk
11. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition
12. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
13. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparation ultracentrifuge
14. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of ApoE1 and ApoE5 isoforms in the Framingham Offspring Study
15. The apolipoprotein E polymorphism: A comparison of allele frequencies and effects in nine populations
16. Relation between baseline and on treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
17. Effects of postmenopausal estrogen replacement therapy on the concentrations and metabolism of plasma lipoproteins
18. Regulation of hepatic apolipoprotein synthesis in the 17α-ethinyl estradiol-treated rat
19. Apolipoprotein E polymorphism affects plasma levels of lipoprotein (a)
20. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis
21. Tamoxifen-induced hypertriglyceridaemia: Seven case reports and suggestions for remedial action
22. Relation between apolipoprotein E phenotype and the changes in lipids during tamoxifen treatment
23. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk
24. Modulation of plasma triglyceride levels by apoE phenotype: A meta-analysis
25. Prolonged postprandial response of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing on apolipoprotein epsilon 4 allele
26. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia
27. Apolipoprotein E4 phenotype increases non-fasting serum triglyceride concentration in infants - The STRIP study